抗血素疗法:当前状况和未来前景
George M Rodgers1, Arash Mahajerin2
1Division of Hematology, University of Utah Medical Center, Salt Lake City, UT, USA.
概括
抗血素 (AT) 治疗对于在AT缺乏症中治疗严重的血栓友至关重要. 本综述探讨了已批准和潜在的用途,指导方针和成本效益,以优化患者的治疗结果.
科学领域:
- 生物化学 生物化学
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 抗血 (AT) 是一种天然的抗凝剂,通过抑制血清蛋白酶,对调节血凝形成至关重要.
- 遗传和获得的AT缺乏症显著增加了静脉血栓栓塞的风险.
- 此外,AT还表现出抗炎性质,并与内皮细胞相互作用.
研究的目的:
- 审查抗血栓治疗的已批准用途.
- 探索潜在的新患者群体进行AT治疗.
- 总结目前关于AT集中成本效益和指导方针的证据.
主要方法:
- 对抗血类药物治疗现有证据的文献综述.
- 已批准的用途,潜在的应用和共识声明的整合.
- 在各种临床环境中分析成本效益数据.
主要成果:
- 抗血素治疗对于优化缺乏AT水平至关重要,特别是在手术和怀孕等高风险情况下.
- 证据支持AT治疗在特定的血栓友爱情背景下,目前正在对更广泛的应用进行研究.
- 成本效益有所不同,需要有针对性的患者选择.
结论:
- 抗血素治疗是AT缺乏症的关键治疗方法,它解决了血栓和潜在的炎症风险.
- 需要进一步的研究来确定从向AT治疗中受益最多的患者子组.
- 优化AT水平对于管理严重血栓形成症和改善患者预后至关重要.
相关概念视频
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
726
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
726
Venous Thrombosis IV: Nursing Management
14
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
14
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
538
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
538
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
192
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
192


